News stories about Merrimack Pharmaceuticals (NASDAQ:MACK) have trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Merrimack Pharmaceuticals earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 48.6601491615026 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Merrimack Pharmaceuticals (MACK) CEO Richard Peters on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Merrimack Pharmaceuticals (MACK) Posts Earnings Results, Misses Expectations By $0.05 EPS (americanbankingnews.com)
- Merrimack (MACK) Reports Wider-than-Expected Q2 Loss (zacks.com)
- Earnings Reaction History: Merrimack Pharmaceuticals Inc, 44.4% Follow-Through Indicator, 4.8% Sensitive (nasdaq.com)
- Merrimack Reports Second Quarter 2018 Financial Results (finance.yahoo.com)
Shares of NASDAQ MACK remained flat at $$5.38 during mid-day trading on Friday. The stock had a trading volume of 68,519 shares, compared to its average volume of 78,516. The company has a market cap of $71.78 million, a PE ratio of -0.95 and a beta of 2.30. Merrimack Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $15.40.
Several equities analysts have recently weighed in on MACK shares. Zacks Investment Research upgraded Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a report on Wednesday, May 2nd. ValuEngine upgraded Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 26th. Robert W. Baird decreased their price objective on Merrimack Pharmaceuticals from $12.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday, June 26th. Finally, JPMorgan Chase & Co. cut Merrimack Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Monday, June 25th.
About Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1.
Featured Story: Diversification in Investing
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.